XML 28 R11.htm IDEA: XBRL DOCUMENT
v3.21.1

REVENUES | 3 Months Ended
--- | ---
Mar. 31, 2021
REVENUES |
REVENUES | NOTE 4 – REVENUES The following table summarizes the Company’s disaggregation of revenues: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended March 31, | ​
(U.S. dollars in thousands) |  | 2021 |  | 2020 | ​
Pfizer | ​ | $ | 4,511 | ​ | $ | 2,016 | ​
Brazil | ​ | $ | — | ​ | $ | 3,015 | ​
Total revenues from selling goods | ​ | $ | 4,511 | ​ | $ | 5,031 | ​
Revenues from license and R&D services | ​ | $ | 6,809 | ​ | $ | 16,615 | ​
​ During the three months ended March 31, 2020, the Company recorded revenue in the amount of $6.7 million following a change in estimate of the total costs expected to be incurred in connection with the Chiesi Agreements.

X
- Definition The entire disclosure pertaining to revenue. + References No definition available. + Details
Name: | plx_RevenueDisclosureTextBlock
Namespace Prefix: | plx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAndDeferredRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration